Genetically Modified T-Cells + Aldesleukin for Melanoma
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to determine the optimal dose and assess the side effects of using genetically modified T-cells and aldesleukin (a type of immunotherapy) to treat stage III-IV melanoma, a type of skin cancer. The treatment involves altering T-cells (a kind of white blood cell) in a lab to enhance their ability to fight melanoma cells when reintroduced into the body. Aldesleukin boosts the T-cells' capacity to attack cancer. Suitable candidates for this trial have stage III or IV melanoma that has spread to other parts of the body. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants a chance to be among the first to receive this new therapy.
Do I have to stop taking my current medications for the trial?
The trial does not specify if you need to stop taking your current medications. However, if you are on steroid therapy or have used systemic steroids recently, you may need to stop, as these are generally not allowed except for low-dose prednisone. It's best to discuss your specific medications with the trial team.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that specially modified T-cells, such as NGFR-transduced autologous T lymphocytes, have been safely used in patients with melanoma. These treatments can lead to strong responses against cancer. In the lab, these T-cells, a type of white blood cell, are altered to better locate and attack cancer cells.
Aldesleukin, also known as Proleukin, is another component of this treatment. Since 1998, it has been used to treat metastatic melanoma, an advanced form of skin cancer that has spread. Although it can cause serious side effects, the FDA has approved it, indicating that its safety is well understood. During trials, some patients experienced severe reactions, but these are well-documented and monitored.
Both components of this treatment have been studied for safety in people with advanced melanoma. Despite the risks, these treatments are not new and have been used in other patients with similar conditions.12345Why do researchers think this study treatment might be promising for melanoma?
Researchers are excited about the potential of NGFR-transduced autologous T lymphocytes for treating melanoma because this approach uses genetically modified T-cells to specifically target cancer cells. Unlike standard treatments like chemotherapy or immune checkpoint inhibitors, this therapy involves engineering a patient's own T-cells to enhance their cancer-fighting abilities. By combining these modified T-cells with high-dose aldesleukin, a drug that boosts immune activity, the treatment aims to create a more potent and targeted attack on melanoma cells. This innovative method offers hope for improved outcomes by harnessing the body's own immune system in a novel way, potentially leading to more effective and personalized cancer care.
What evidence suggests that genetically modified T-cells followed by aldesleukin might be an effective treatment for melanoma?
Research shows that specially modified T-cells, such as NGFR-transduced autologous T lymphocytes, effectively treat melanoma. This treatment, part of the current trial, involves tumor-infiltrating lymphocyte (TIL) therapy, which has been approved for melanoma and has proven effective. Participants in this trial will receive these modified T-cells combined with aldesleukin, a drug that boosts white blood cells. Studies indicate that aldesleukin can enhance T-cells' ability to fight melanoma and has helped shrink or slow tumor growth in 5–27% of patients with advanced melanoma. These findings suggest that this combination could be a promising treatment for advanced melanoma.26789
Who Is on the Research Team?
Rodabe N. Amaria
Principal Investigator
M.D. Anderson Cancer Center
Are You a Good Fit for This Trial?
This trial is for adults with stage III-IV melanoma who have adequate lung function, no severe psychiatric diseases, and are not pregnant or nursing. Participants must not have had recent cancer treatments, organ transplants, significant medical illnesses, or be on chronic steroids. They need measurable melanoma lesions suitable for T-cell generation and agree to use birth control.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Chemotherapy
Patients receive cyclophosphamide and fludarabine phosphate intravenously to prepare for T-cell infusion
T-Cell Infusion and Aldesleukin Treatment
Patients receive TGFb DNRII-transduced autologous TIL and NGFR-transduced autologous T lymphocytes followed by high-dose aldesleukin
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Aldesleukin
- NGFR-transduced Autologous T Lymphocytes
Find a Clinic Near You
Who Is Running the Clinical Trial?
M.D. Anderson Cancer Center
Lead Sponsor
National Cancer Institute (NCI)
Collaborator